Introducing Evidence-based Keto: Your no-hype guide to the ketogenic diet
We've spent the past year analyzing the research on the keto diet, and have just released Evidence-based Keto.
Clocking in at over 200 pages with 500+ references, it's the unbiased guide you need to the ketogenic diet.
Summary of Evodia rutaecarpa
Primary Information, Benefits, Effects, and Important Facts
Evodia rutaecarpa is the plant which bears the berries evodia fructae (Fruits of Evodia), which are eaten in Traditional Chinese Medicine as a warming technique. The plant is also touted to reduce pain and gastrointestinal distress, and be anti-cancer.
It has been investigated as a fat burner, but no significantly promising evidence has been shown at this moment in time. It does appear to make animals feel hotter and quite reliably so, but this is a combination of increased heat expenditure (which is a fat burning effect) and minimizing the perception of cold via TRPV1 agonism, similar to the red pepper extract capsaicin. This combination may make one feel warmer despite not increasing caloric expenditure much.
Two studies have been conducted on animals showing anti-obesity effects, but these appear to not be related to the warmth effect of Evodia fruit and they do not necessarily mean it can be used to burn fat.
Beyond that, it shows promise as an anti-cancer agent through some relatively unique mechanisms and shows limited use as a supplement; taking the active ingredients (evodiamine, rutaecarpine) out of the fruit and into a supplemental capsule drastically reduces oral bioavailability. Isolated supplements may be quite worthless outside of the colon and stomach, with fruit or an ethanolic fruit extract being needed to reach the blood in appreciable amounts
Things To Know & Note
Also Known As
Wuzhuyu, Wu Zhu Yu, Wu Zhu Yu Tang, Evodiae Fructus, Evodia Fruit, Evodia Fructae
Do Not Confuse With
Evodiamine (bioactive), Rutaecarpine (bioactive)
Goes Well With
The Rhizome of Coptis Chinesis (increases the amount of Evodia absorbed)
Caution NoticeExamine.com Medical Disclaimer
Isolated evodiamine and rutaecarpine have very bad absorption rates in isolation; this is not worrisome if your target is the stomach or colon (easing digestion) but if you want it in your blood you may need to consume the whole fruits of Evodia or at least an ethanolic extract of the fruits
Significant interactions of rutaecarpine and caffeine; the former effectively negates the effects of the latter
How to Take Evodia rutaecarpa
Recommended dosage, active amounts, other details
There are currently no human studies on evodia rutaecarpa berries.
Traditional usage of the berries involves making a decoction using 3-9g of the berries and then dividing said decoction into either two servings daily (morning and evening) or thrice daily (morning, noon, and evening)
ON SALE UNTIL TOMORROW: Evidence-based Keto
Unbiased truth on keto and long-term effects on health, safety, pre-existing conditions, losing weight, and more.Learn the latest on keto
Everything you need to know about the keto diet
When we asked our users what they wanted us to cover, many of them mentioned the keto diet.
So we listened. We spent the year looking up the research on the ketogenic diet to help guide you in your journey.
With Evidence-based Keto, Examine.com gives you all the scientific research, but in understandable language with tons of informative infographics. No opinion, no bias, no conflict of interest.
If you’re interested in keto, this is a must-have unbiased source.
Scientific Research on Evodia rutaecarpa
Click on any below to expand the corresponding section. Click on to collapse it.
Evodia Rutaecara, the dried unripe fruit of which is also known as Wu zhu yu (Wu Zhu Yu, interchangeably) or Evodia Fruit, is a herb used in Traditional Chinese Medicine at doses of 3-9 grams (of the berries) thrice a day for the purposes of warmth, intestinal comfort (specifically; to alleviate abdominal pain, acid regurgitation, nausea and diarrhea), dysmenorrheal, and fighting inflammation and infections. It is frequently used in a combination supplement called Wu Zhu Yu Tang, which consists of Evodia fruit with Jujube Fruit and Panax Ginseng (1:1:1 ratio) and Ginger root (twice the amount of any one other ingredient) which is a decoction used for hypertension or as Zuo jin wan which is used for gastrointestinal distress alongside Rhizoma Coptidis at a 1:6 ratio (Evodia:Coptidis). Another decoction exists called Fan zuo jin wan, which is Rhizome Coptidis and Evodia in the inverse ratio.
When consuming Wu Zhu Yu Tang in a traditional manner, the estimated intake of Rutaecarpine is 16mg daily (extrapolated from the average intake of 9g berry extract taken thrice a day) and slightly higher levels of evodiamine.
Traditionally eaten when you are cold; apparently warms you up real nicely while making your stomach and intestines happy. Also supposedly fights cancer
Evodiamine and dehydroevodiamine, two forms of one of the main compounds belong to the 'quinazolinocarboline alkaloid' class  Evodiamine is found in the range of 0.2-1.6%, with the lower range of the samples tending to have more dehydroevodiamine (0.12-0.86%), suggesting interconversion
Rutaecarpine and its metabolite 10-hydroxyrutaecarpine (as well as the former's glycoside, rutaecarpine-10-O-rutinoside) the forms of the other main quinazolinocarboline alkaloid. Rutaecarpine is at around 0.15-0.55% in evodia fruit.
Flavonoids and flavonoid glycosides such as isorhamnetin-7-O-rutinoside and diosmetin-7-O-β-d-glucopyranoside
Acylgluconic acids such as trans-feruloylgluconic acid and trans-caffeoylgluconic acid at 0.00003% and 0.0006% whole fruit, respectively (although can be isolated in a methane-ethanol extraction)
Pthalic acid dibutyl ester at 8mg per 299.5g (miniscule)
Essential oils of β-pinene (72.82%), 1R-α-pinene (8.90%), and β-myrcene (1.99%)
Main collection of compounds are the quinazolinocarboline alkaloids, evodiamine and rutaecarpine (named after the two parts of the herbs name respectively, Evodia Rutaecarpa). The flavonoids, limonoid, and other alkaloid compounds are most likely also bioactive, and the Inositol content is quite respectable and may be bioactive. The content of the main bioactives is relatively low, however
Pictured below are the two main bioactives typically attributed to Evodia Rutaecarpa.
Despite the similarities in action to capsaicin, which is hot pepper extract; isolated evodiamine possesses no significant taste nor spiciness. A large amount of crystal data for evodiamine can be found here.
After oral administration of a Wu zhu yu decoction (Evodia, Panax Ginseng, and Jujubae Fructus at a 1:1:1 ratio, and Ginger at twice the amount of any one ingredient; ethanolic extract) given at 12g/kg orally (2.4g/kg Evodia ethanolic extract) the following parameters were found for various compounds in Evodia Rutaecarpa.
Evodiamine had a half-life of 0.93 ± 0.45 hours, a Tmax of 1.49 ± 0.22 hours, a Cmax of 19.52 ± 8.17ug/mL, and an AUC of 71.27 ± 15.52ug/h/mL. Another study finding a Cmax of 49 ± 19ng/mL after 500mg/kg ingestion evodiamine in isolation, along with the former pinpoint a bioavailability of pure evodiamine at around 0.1% in isolation and slightly higher as Evodia Rutaecarpa. Another study using basic Evodia ethanolic extract found that 40mg/kg of an extract (35% evodiamine by weight, so 14mg/kg) conferred a Cmax of 164.8 ± 65.1ug/mL; relative to the previous study, this suggests that a dose of 35.7-fold lower, if taken in an ethanolic berry extract, has an average peak blood concentration 3.36-fold higher. The Tmax in all studies seems to hover between 30-60 minutes, however.
Rutaecarpine had a half-life of 0.98 ± 0.39 hours, a Tmax of 1.26 ± 0.23 hours, a Cmax of 13.46 ± 7.03ug/mL, and an AUC of 62.44 ± 18.85ug/h/mL. Another study found low bioavailability of Rutaecarpine in isolation (Concentration of 2.4 ± 3.0ng/ml 30 minutes after 40mg/kg crude drug) but administering Rutaecarpine as a solid dispersion (mechanical technique) increased the concentration in the blood 7.5-fold (to 18.1 ± 1.8ng/mL) Nanoemulsions have also shown benefit in increasing the absorption rates. A basic concentration ethanolic extract of Wu Zhu Yu (pre-ripe) berries (40% of a 40mg/kg oral ingestion, so 16mg/kg), reaches blood levels of 215.3 ± 80.4ug/mL in rats. The improvement in bioavailability is similar to that seem with evodiamine, where an oral dose 2.5-fold lower can have a blood concentration 89.7-fold higher if consumed in the form of a concentrated berry ethanolic extract. Similar to evodiamine, Tmax of all studies hovered around 30-60 minutes regardless of the Cmax.
Dehydroevodiamine had a half life of 0.79 ± 0.21 hours, a Tmax of 1.07 ± 0.15 hours, a Cmax of 7.64 ± 0.63ug/mL, and an AUC of 12.39 ± 2.71ug/h/mL. In isolation, dehydroevodiamine appears to have better bioavailability than the previous two molecules (averaged at 15.35% in rats) yet at least one study has investigated Dehydroevodiamine and its circulating levels in conjunction with other plants, and consumption of Evodia alongside Rhizoma Coptidis (1:6 ratio, combination known as Zuojinwan) appears to preserve the Tmax (1.6 hours without, 1.8 hours as Zuojinwan) yet elevate the Cmax 2.66-fold (15,383 ± 7166 to 40,992 ± 21,052) while reducing the Tmax (3.5 ± 3.0 hours to 1.5 ± 1.1) and causing a large increase in the AUC to infinity by 174% (68,134 ± 19,162 to 186,715 ± 39,211).
The three main components of Evodia Rutaecarpa all appear to be highly subject to herb-herb interactions, where their absorption and circulating levels are much higher when in the form of the whole plant rather than isolated chemical and even higher when paired in Traditional Chinese Medicine decoctions. It may be worthless to supplement evodiamine or rutacarpine in isolation if your goal is to get it to your blood (fine if you want it in the colon) due to poor bioavailability
10-hydroxyrutaecarpine had a Cmax of 0.76 ± 0.16ug/mL and a Tmax of 0.50 ± 0.25 with an AUC of 9.32 ± 2.93ug/h/mL, but an undetectable half-life.
1-methyl-2-n-nonyl-4(1H)quinolone had a Cmax of 3.16 ± 1.28ug/mL at a Tmax of 0.77 ± 0.15 hours, its AUC was 9.83 ± 1.51ug/h/mL and half-life was 2.18 ± 0.47 hours.
Evocarpine had a half-life of 0.53 ± 0.18 hours and a Tmax of 0.88 ± 0.17 hours, with a Cmax of 11.53 ± 6.97ug/mL and an AUC of 33.66 ± 10.52ug/h/mL.
Dihydroevocarpine had a half-life of 0.49 ± 0.21 hours and a Tmax of 0.79 ± 0.15 hours, a Cmax of 6.05 ± 2.87ug/mL and an AUC of 16.53 ± 5.79ug/h/mL.
Isorhamnetin-7-O-rutinoside had a half-life of 0.67 ± 0.30 hours, a Tmax of 0.95 ± 0.25 hours, a Cmax of 2.21 ± 0.32ug/mL, and an AUC of 7.54 ± 1.03ug/h/mL.
Diosmetin-7-O-β-d-glucopyranoside had a half-life of 0.95 ± 0.51 hours, a Tmax of 1.53 ± 0.17 hours, a Cmax of 1.73 ± 0.51ug/mL, and an AUC of 9.41 ± 3.57ug/h/mL.
In general, all compounds tend to have low to moderate bioavailability and relatively rapid pharmacokinetic profiles; hitting their peak concentrations in the blood before or at an hour after administration. Evodiamine and Rutaecarpine seem to really benefit from being ingested as a whole berry rather than isolated compounds
Evodiamine appears to be carried in the blood and distributed into organs, and one study in rats found the volume of distribution to be 560ml/kg and found evodiamine (and metabolites) to be deposited in the liver, kidneys, heart, lung, and adipose tissue at a concentration higher than plasma, and other tissues it diffused in were at lower levels relative to plasma.
When investigating dehydroevodiamine, it has been demonstrated that this molecule can cross the blood brain barrier of the rat and enter the brain via linear kinetics. When a plasma level of 4.82 ± 1.55 μg/mL was measured in rats, the concentrations in the brain were 1.11 ± 0.4 (cortex), 0.93 ± 0.24 (hippocampus), 0.64 ± 0.28 (striatum), 1.13 ± 0.33 (cerebellum), 1.04 ± 0.3 (brain stem), and 1.18 ± 0.18 μg/g (everything else). On average, concentrations of dehydroevodiamine that circulate in the brain are 3-4x lower than plasma levels.
Dehydroevodiamine appears to be subject to P450, and its circulating metabolites consist of five glucuronides (two identified ones at the 10 and 11 carbon) and one sulfate (Dehydroevodiamine-12-sulfate) in freely moving rats.
Rutaecarpine is metabolites mostly by cytochrome P450 1A2 (aromatase) at the 10, 11, and 12 carbon positions, although 3 is not unheard of and into the four metabolites of 3, 10, 11, or 12-hydroxyrutaecarpine. Metabolism into 3- and 10- hydroxyrutaecarpine is strongly inhibited by ketoconazole, suggesting it is metabolized by CYP3A4; the other two metabolites (11- and 12-hydroxyrutaecarpine) are metabolized by CYP1A but can also be metabolized by CYP3A4 and CYP2D6.
Interestingly, Rutaecarpine's metabolite 10-hydroxyrutaecarpine, which is produced by CYP3A4, can act as an aromatase inhibitor, inhibiting CYP1A1 and CYP1A2 (two aromatase isomers) with IC50 values of 2.56 ± 0.04uM and 2.57 ± 0.11uM, respectively. Rutaecarpine also shares aromatase inhibitory potential with preference for CYP1A2, but prolonged (3 days) ingestion of rutaecarpine, Evodia, or a Wu Zhu Yu Tang mixture of which effects are attributable to Evodia may cause CYP1A induction and thus the opposite effects of inhibition.
Rutaecarpine technically is an aromatase inhibitor, but causes increased aromatase activity relatively quickly
24 hours after administration of evodiamine, 82% of evodiamine and its metabolites are excreted with 23% of that excretion occuring via the urine and the rest via feces.
After an oral bolus of 500mg/kg bodyweight dehydroevodiamine, most of it is conjugated by P450; the amount of unchanged metabolite in the urine and feces are 0.5% and 6% of the initial oral dose, respectively.
Rutaecarpine has a large amount of fecal excretion (~42%) after oral ingestion, and its main urinary metabolite is 10-hydroxyrutaecarpine, which is the result after rutaecarpine interacts with the CYP1A2 enzyme.
Evodiamine is an agonist of the vanilloid receptor, a property also seen with the red pepper extract capsaicin. It appears to be slightly less potent than capsaicin, requiring thrice the concentration in vitro to maximally stimulate the receptors.
Through interactions with vanilloid receptors, Evodia Rutacarpa possesses antinocioreceptive (pain relieving) effects.
Evodia Rutacarpa has been investigated for its effects on body fat due to it being used traditionally as a warming agent and as a 'hot herb'; references to thermogenesis in the Chinese literature.
1-3mg/kg bodyweight evodiamine administered subcutaneously was able to drop core body temperature by 1C in fasted mice, while fed mice required 10mg/kg to achieve the same effect. These drops in internal temperature were matched with extra heat dissipation from the rat tail, indicative of thermogensis, almost immediately. The ability of evodiamine's mechanisms of action, TRPV1 activation, to make areas tolerant to the cold is also a possibility; cold hyposensitivty (responding less to the cold) indirectly increases perceptions of heat.
This heat production, however, is not the sole reason for evodiamine's fat burning effects.
Evodiamine has been traditionally used to increase warmth, and it appears it might increase both heat production and reduce the perception of cold. However, the studies from which this data is drawn are not suited to human oral consumption of Evodia
When incubated in preadipocytes, evodiamine is able to activate the MAPK cascade, which reduces insulin-induced phosphorylation of Akt and also PPARγ activity, which thus decreases preadipocyte differentiation. The classical mechanisms of evodiamine, as agonist of TRPV1 receptors, can also work to reduce preadipocyte differentitation; thus there may be two similar mechanisms of action occurring.
Inhibition of preadipocyte differentiation has been noted elsewhere relatively dose-dependently, but most significantly at 4uM concentration or above and in vivo following injections of evodiamine. The authors mentioned this was 'negative crosstalk' with insulin signalling, which interferes with its effects.
Evodiamine appears to exert anti-obesity effects via inhibiting preadipocyte differentiation
One study on mice fed 0.03% evodiamine and rats fed 1.35% evodia extract (standardized to 0.02% evodiamine) in their obesity causing diets over 21 days showed no difference in food intake compared to control (important to note, as the adverse taste of capsaicin screws with food intake in animal studies) but a small reduction in fat mass on mice (28% reduction of perirenal fat, 11% less epididymal fat) and decreases in weight (-10.3% relative to control) and increased thermogenesis; suggesting evodiamine may exert an anti-obesity effect. Another study investigating mechanisms fed 0.03% evodiamine for 6 months and noted significant anti-obesity effects by reducing the rate of weight gain, and this persisted in UCP1 knockout mice who were unable to produce heat from evodiamine.
Evodiamine has been shown to prevent fat gain to a degree in mice fed a diet that induces fat gain, but has not yet been demonstrated to induce fat loss. The heat producing effects of evodiamine may not be related to attenuation of fat gain
When evodiamine is incubated with endothelial cells, it is able to inhibit IL-1α (at 10uM) and Thromboxane B2 (TXB2) secretion (at 10uM) in response to inflammatory signals (LPS) and was able to decrease the levels of E-selectin on endothelial cells; although no response was dose-dependent.
Both evodiamine and rutaecarpine have been shown to inhibit PGE(2) production in macrophages that are stimulated by LPS (a pro-inflammatory signal) and in macrophages undergoing hypoxia. Evodiamine was further able to prevent upregulation of COX-2, a pro-inflammatory enzyme, while rutaecarpine was ineffective at doing so. Dehydroevodiamine can also reduce COX-2 activity and mRNA translation while rutaecarpine seems to be more of a direct inhibitor rather than manipulating protein content of COX enzymes, able to inhibit both COX-1 and COX-2 with IC50 values of 8.7uM and 0.28uM, respectively.
Another compound, goshuyuamide II, was demonstrated to be able to inhibit 5-LOX and reduce synthesis of leukotrienes.
The combination decoction of Evodia Fructae and Coptidis Chinensis 1:6 (Zuo Jin Wan) has been shown in vitro to inhibit both NF-kB translocation and AP-1 signalling in HepG2 (liver) cells with IC50 values of >200 and 22.9μg/ml for AP-1 and NF-kB, respectively for the combination. Berberine was able to inhibit AP-1 and NF-kB with IC50 values of 9.5 and 50μM, respectively, while Evodiamine was only inhibitory on AP-1, and to lesser potency than Berberine.
Evodiamine has been shown to inhibit NF-kB activation in macrophages at 1-10uM concentration in response to pro-inflammatory signals.
Topoisomerases (I and II) are enzymes that regulate the separating of DNA strands so DNA can be replicated. DNA gets unwound when a phenolic nucleophile attacks the 3' end of DNA, causing it to bind to Tyr723 on the TopoI enzyme, which allows DNA to unwind and relax; it is eventually then attacked by the 5' end of the DNA and the two ends reunite in a process called religation. Topoisomerase I basically holds the 3' end for a bit while DNA gets replicated. Topoisomerase I inhibitors can prevent DNA from religating, and induce cytotoxicity (cell death); which is actually a good idea for cancer cells that overexpress Topoisomerase I as they die much faster than regular cells.
Evodiamine has an IC50 value of 6.02uM in MCF-7 breast cancer cells, which express high levels of Topoisomerase I, and only slightly less cytotoxic than Camptothecin which is a research standard drug. Evodiamine is able to prevent DNA religation in a concentration-dependent manner in a similar manner to Camptothecin, by making a complex with Topoisomerase I and the 3' DNA strand it holds. Evodiamine has demonstrated cytotoxixity in breast cancer cells elsewhere and was shown in adriamycin-resistant breast cancer cells to induce cell death both in vitro and in vivo with a potency greater than that of paclitaxel.
Evodiamine is a dual catalytic topoisomerase I and II inhibitor, and shows efficacy against some cells that are resistant to the more potent topoisomerase I inhibitor Camptothecin, and does not seem to induce DNA damage. A flavanoid from evodiamine also possesses dual inhibitory potential.
A mechanism by which Evodia Fructs may be anti-cancer; awaits more studies to see its overall clinical relevance, but its dual inhibition is novel and promising at least
Apoptosis, or the event of cell death, is an important biomarker in cancer therapy.
Evodia components have been demonstrated to induce apoptosis in gastric cancer cells (SGC-7901) and (N-87), Breast cancer cells (MCF-7) and (NCI/ADR-RES), Liver cells (HepG2), Leukemia cells (HL-60) (THP-1) and (U937), Lung (H-460) and (LLC), Colon (COLO-205), Thyroid (ARO), Melanoma (A375-S2), and (B16-F10), Cervical Cancer (HeLa), fibrosarcoma (L929), and has been demonstrated in vivo to inhibition the Sarcoma-180 tumor model when fed as the decoction Zuo jin wan. More often than not, these effects are attributed to Evodiamine and its metabolites although in some instances flavanoid glycosides are to credit.
When rutaecarpine (active indole in Evodia) is fed to rats, the AUC and Cmax values of caffeine are significantly reduced; meaning rutaecarpine can reduce the exposure of caffeine to the body. This also extends to the similar xanthine compound theophylline. These effects extend to consumption of Evodia itself, and combination decoctions such as Wu Zhu Yu Tang.
This effect is rather significant; pretreatment of 80mg/kg oral Rutaecarpine daily for 3 days (a high dose, but its bioavailability is unaugmented) in rats reduced the Cmax to 31% of the control group, the Tmax to 22%, the AUC to 5% of control, and reduced the half-life from 0.73+/-0.07 hours to 0.27+/-0.1 hours. Similar trends were seen for all metabolites of caffeine (paraxanthine, theophylline, theobromine)
Rutaecarpine is able to induce (increase) activity of various hepatic enzymes such as CYP1A2, CYP2B, and CYP2E1; CYP2E1 induction is seen at 80mg/kg oral ingestion in rats while only 20mg/kg is needed for CYP1A2. As caffeine is highly metabolized by CYP1A and CYP2E1, their increased activity causes greater metabolism of caffeine in a shorter time frame and thus limits systemic exposure.
Rutaecarpine appears to potently suppress the circulating levels of caffeine via increasing hepatic and intestinal degradation; a highly antagonistic compound
The pair of Evodia fruit and Rhizoma Coptidis (rhizome of Coptis chinensis) is known as Zuo jin wan and is a Traditional Chinese Medicine decoction for acute gastrointestinal distress. It is paired with 6 parts Rhizoma Coptidis to 1 part Evodia Fructus (6:1 ratio). Conversely, reversing the ratio and favoring Evodia in the 6:1 ratio is the basis for Fan zuo jin wan, another Chinese decoction. These formulas are indicated for short-term use only.
Coptis and Evodia form a dichotomy of cold and hot (Yin and Yang), respectively, where Coptis reportedly induces a cold state and a seeking process for a warm environment while Evodia induces heat and the seeking behavior for a cold environment. Coptis seems to be able to reduce internal body temperature and oxygen consumption in mice and prolong time spent in a warm environment (as assessed by warm pads) while Evodia increases time in a cold environment, and increases both oxygen consumption and body temperature. Zuo jin wan is classified as cold whereas Fan zuo jin wan is classified as warm. The only currently known biomarker for this temperature preference is liver ATPase activity.
Coptis Chinensis and Evodia Fructus appear to be mostly antagonist to each other in how they are seen to affect temperature; yet they are used together in decoctions and mixtures (for acute conditions and short-term usage; a 'harmonizing of hot and cold' treatment strategy). The historical reports of Evodia's 'heat' and Coptis's 'cold' properties actually do seem to have some merit, as evidenced by the rat preference tests trying to bioregulate their temperature
When looking at the pharmacokinetics of the combination, Rhizoma Coptidis appears to benefit the pharmacokinetics and circulating levels of some bioactives in Evodia such as dehydroevodiamine by about 274% of the value of Evodia alone despite the same oral dosage (AUC value). Evodia seems to either not significantly affect the pharmacokinetics of some Coptidis molecules such as coptisine (acutely) yet increase general absorption but can reduce the AUC of various alkaloids (coptisine, palmatine, jateorrhizine) after prolonged ingestion and reduce the AUC and Cmax values of the berberine content of Coptidis Rhizoma either chronically or acutely. This was hypothesized to be secondary to Evodia Fructus pretreatment enhancing the expression of hepatic UGT1A1, a sulfation enzyme, which conjugated compounds in Coptidis Rhizoma.
Coptidis chinensis rhizome enhances the bioavailability and circulating amount of co-ingested Evodia fruit, but Evodia fruit hinders the absorption and circulating amount of the active ingredients of Coptidis Chinensis; almost as if the former is sacrificing itself for the latter
Paeoniflorin is the main bioactive found in the herb Paeonia Lactiflora, and its bioavailability and circulating amounts are enhanced by various herbs. Although not to the same degree of Fennel fruit (which increases bioavailability to 226.02% of the level of Paeoniflorin in isolation), consumption of Paeoniflorin alongside Evodia fruit elevates relative absorption to 123.62%.
Paeonia Lactiflora doesn't do much for Evodia, but Evodia enhances the absorption of Paeonia Lactiflora bioactives
- Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components.
- Ueng YF, et al. Effects of Wu-chu-yu-tang and its component herbs on drug-metabolizing enzymes. Jpn J Pharmacol. (2002)
- Ueng YF, et al. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450. Drug Metab Dispos. (2006)
- Cai F, et al. Evodiamide. Acta Crystallogr Sect E Struct Rep Online. (2012)
- Hu CQ, Li F, Yang XW. Simultaneous determination and pharmacokinetic analysis of seven alkaloids and two flavonoids from rat plasma by HPLC-DAD after oral administration of Wuzhuyu decoction. J Asian Nat Prod Res. (2012)
- Zhou Y, et al. Quantitative analyses of indoloquinazoline alkaloids in Fructus Evodiae by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. (2006)
- Hu CQ, Li KK, Yang XW. New glycosidic alkaloid from the nearly ripe fruits of Euodia rutaecarpa. J Asian Nat Prod Res. (2012)
- Chuang WC, et al. Contents of constituents in mature and immature fruits of evodia species. Planta Med. (1999)
- Lin LC, et al. Pharmacokinetics and urine metabolite identification of dehydroevodiamine in the rat. J Agric Food Chem. (2012)
- Huang X, Li W, Yang XW. New cytotoxic quinolone alkaloids from fruits of Evodia rutaecarpa. Fitoterapia. (2012)
- Zhao MY, Yang XW. Two new acylgluconic acids from the nearly ripe fruits of Evodia rutaecarpa. J Asian Nat Prod Res. (2008)
- Matsuda H, et al. Antinociceptive and anti-inflammatory activities of limonin isolated from the fruits of Evodia rutaecarpa var. bodinieri. Planta Med. (1998)
- Teng J, Yang XW. A new limonoid from the fruits of Evodia rutaecarpa (Juss.) Benth. Pharmazie. (2006)
- Cai GX, et al. Comparative analysis of essential oil components of Evodia rutaecarpa (Juss.) Benth. var. officinalis (Dode) Huang and Evodia rutaecarpa (Juss.) Benth. Nat Prod Res. (2011)
- Zhang YT, et al. Enhanced transdermal delivery of evodiamine and rutaecarpine using microemulsion. Int J Nanomedicine. (2011)
- Determination and pharmacokinetics of evodiamine in the plasma and feces of conscious rats.
- Xu S, et al. Pharmacokinetic comparisons of rutaecarpine and evodiamine after oral administration of Wu-Chu-Yu extracts with different purities to rats. J Ethnopharmacol. (2012)
- Ding JS, et al. Solid dispersion of rutaecarpine improved its antihypertensive effect in spontaneously hypertensive rats. Biopharm Drug Dispos. (2008)
- Study On Absorption Mechanism Of Rutacarpine.
- Yan R, et al. Relative Determination of Dehydroevodiamine in Rat Plasma by LC-MS and Study on its Pharmacokinetics. J Chromatogr Sci. (2012)
- Komatsu K, Wakame K, Kano Y. Pharmacological properties of galenical preparation. XVI. Pharmacokinetics of evodiamine and the metabolite in rats. Biol Pharm Bull. (1993)
- Ahn SH, et al. Pharmacokinetic characterization of dehydroevodiamine in the rat brain. J Pharm Sci. (2004)
- Don MJ, et al. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorg Med Chem Lett. (2003)
- Lee SK, et al. Characterization of in vitro metabolites of rutaecarpine in rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. (2004)
- Jan WC, et al. Elimination of rutaecarpine and its metabolites in rat feces and urine measured by liquid chromatography. Biomed Chromatogr. (2006)
- Ueng YF, et al. The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. Drug Metab Dispos. (2002)
- Ueng YF, et al. Induction of cytochrome P450-dependent monooxygenase in mouse liver and kidney by rutaecarpine, an alkaloid of the herbal drug Evodia rutaecarpa. Life Sci. (2001)
- Kobayashi Y, et al. The bronchoconstrictive action of evodiamine, an indoloquinazoline alkaloid isolated from the fruits of Evodia rutaecarpa, on guinea-pig isolated bronchus: possible involvement on vanilloid receptors. Planta Med. (2000)
- Kobayashi Y, et al. The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors. Planta Med. (2001)
- Matsuda H, et al. Antinociceptive activities of 70% methanol extract of evodiae fructus (fruit of Evodia rutaecarpa var. bodinieri) and its alkaloidal components. Biol Pharm Bull. (1997)
- Kobayashi Y, et al. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med. (2001)
- Callsen MG, et al. Cold hyposensitivity after topical application of capsaicin in humans. Exp Brain Res. (2008)
- Wang T, et al. Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology. (2008)
- Pearce LV, et al. Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol Chem. (2004)
- Zhang LL, et al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res. (2007)
- Hu Y, et al. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia. (2010)
- Bak EJ, et al. Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes. Int J Obes (Lond). (2010)
- Hu YY, He KW, Guo RL. Six alkaloids inhibit secretion of IL-1α, TXB(2), ET-1 and E-selectin in LPS-induced endothelial cells. Immunol Invest. (2012)
- Choi YH, et al. Anti-inflammatory principles from the fruits of Evodia rutaecarpa and their cellular action mechanisms. Arch Pharm Res. (2006)
- Liu YN, et al. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock. (2009)
- Noh EJ, et al. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci. (2006)
- Moon TC, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. (1999)
- Teicher BA. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol. (2008)
- Chan AL, et al. Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules. (2009)
- Xu ML, et al. Cytotoxicity and DNA topoisomerase inhibitory activity of constituents isolated from the fruits of Evodia officinalis. Arch Pharm Res. (2006)
- Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo.
- Pan X, et al. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine. (2012)
- Rasul A, et al. Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. Oncol Rep. (2012)
- Zhu LH, et al. Induction of apoptosis by evodiamine involves both activation of mitotic arrest and mitotic slippage. Oncol Rep. (2011)
- Peng QX, et al. Proportion of Coptidis rhizoma and Evodiae fructus in the compound preparation: its effect in inducing apoptosis of SGC-7901 cells. Nan Fang Yi Ke Da Xue Xue Bao. (2011)
- Zhang Y, et al. Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa. J Asian Nat Prod Res. (2004)
- Liao CH, et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis. (2005)
- Chao DC, et al. Inhibitory effects of Zuo-Jin-Wan and its alkaloidal ingredients on activator protein 1, nuclear factor-κB, and cellular transformation in HepG2 cells. Fitoterapia. (2011)
- Lee TJ, et al. Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells. Mol Cancer Ther. (2006)
- Ogasawara M, et al. Anti-invasive and metastatic activities of evodiamine. Biol Pharm Bull. (2002)
- Yang ZG, Chen AQ, Liu B. Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205). Chem Biodivers. (2009)
- Dong L, et al. Effects of Coptis chinensis and Evodia rutaecarpa water extract on DMH-induced precancerous lesion of colon. Zhongguo Zhong Yao Za Zhi. (2010)
- Chen MC, et al. Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J Cell Biochem. (2010)
- Wang C, et al. Effect of protein kinase C on human melanoma A375-S2 cell death induced by evodiamine. Yao Xue Xue Bao. (2005)
- Wang C, et al. Roles of SIRT1 and phosphoinositide 3-OH kinase/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death. J Pharmacol Sci. (2005)
- Zhang Y, et al. Evodiamine induces tumor cell death through different pathways: apoptosis and necrosis. Acta Pharmacol Sin. (2004)
- Fei XF, et al. Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci. (2003)
- Wang XN, et al. In vivo inhibition of S180 tumors by the synergistic effect of the Chinese medicinal herbs Coptis chinensis and Evodia rutaecarpa. Planta Med. (2009)
- Wang XN, et al. Anti-cancer activity of Zuojinwan in vivo and influence to tumor markers in mice transplanted with sarcoma 180. Zhongguo Zhong Yao Za Zhi. (2008)
- Noh K, et al. Effects of rutaecarpine on the metabolism and urinary excretion of caffeine in rats. Arch Pharm Res. (2011)
- Tsai TH, Chang CH, Lin LC. Effects of Evodia rutaecarpa and rutaecarpine on the pharmacokinetics of caffeine in rats. Planta Med. (2005)
- Ueng YF, et al. Alteration of the pharmacokinetics of theophylline by rutaecarpine, an alkaloid of the medicinal herb Evodia rutaecarpa, in rats. J Pharm Pharmacol. (2005)
- Lee SK, et al. Induction of cytochrome P450s by rutaecarpine and metabolism of rutaecarpine by cytochrome P450s. Planta Med. (2004)
- Yang HB, et al. COLD or HOT natural attribute of Zuojinwan and Fanzuojinwan based on temperature tropism of mice. Yao Xue Xue Bao. (2010)
- Ren YS, et al. COLD and HOT nature of Coptis & Evodia and their prescriptions investigated with diet restriction/cold-water swimming mice models. Yao Xue Xue Bao. (2009)
- Zhao H, et al. Expression of the difference between the Cold (Han) and Hot (Re) natures of traditional Chinese medicines (Strobal and Rhubarb) based on the cold/hot plate differentiating assay. Sci China C Life Sci. (2009)
- Zhou C, et al. Investigation of the differences between the "Cold" and "Hot" nature of Coptis chinensis Franch and its processed materials based on animal's temperature tropism. Sci China C Life Sci. (2009)
- Yan R, et al. Comparative pharmacokinetics of dehydroevodiamine and coptisine in rat plasma after oral administration of single herbs and Zuojinwan prescription. Fitoterapia. (2011)
- Ma BL, et al. Influences of Fructus evodiae pretreatment on the pharmacokinetics of Rhizoma coptidis alkaloids. J Ethnopharmacol. (2011)
- Yang ZY, et al. Study on enhancing bioavailability of paeoniflorin by combined use with Chinese herbs for inner-warming. Zhongguo Zhong Xi Yi Jie He Za Zhi. (2005)
- Yang XW, et al. Studies on the alkaloid constituents of Evodia rutaecarpa (Juss) Benth var. bodinaieri (Dode) Huang and their acute toxicity in mice. J Asian Nat Prod Res. (2006)